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The interpretation and signiﬁcance of DNA adduct
data, their causal relationship to mutations, and their
role in risk assessment have been debated for many
years. An extended effort to identify key questions
and collect relevant data to address them was
focused on the ubiquitous low MW N7-alkyl/
hydroxyalkylguanine adducts. Several academic,
governmental, and industrial laboratories collabo-
rated to gather new data aimed at better under-
standing the role and potential impact of these
adducts in quantiﬁable genotoxic events (gene muta-
tions/micronucleus). This review summarizes and
evaluates the status of dose–response data for DNA
adducts and mutations from recent experimental
work with standard mutagenic agents and ethylene
oxide and propylene oxide, and the importance for
risk assessment. This body of evidence demonstrates
that small N7-alkyl/hydroxyalkylguanine adducts
are not pro-mutagenic and, therefore, adduct forma-
tion alone is not adequate evidence to support a
mutagenic mode of action. Quantitative methods for
dose–response analysis and derivation of thresholds,
benchmark dose (BMD), or other points-of-departure
(POD) for genotoxic events are now available. Inte-
gration of such analyses of genetox data is neces-
sary to properly assess any role for DNA adducts in
risk assessment. Regulatory acceptance and applica-
tion of these insights remain key challenges that only
the regulatory community can address by applying
the many learnings from recent research. The neces-
sary tools, such as BMDs and PODs, and the exam-
ple datasets, are now available and sufﬁciently
mature for use by the regulatory community. Environ.
Mol. Mutagen. 2018. © 2018 The Authors. Environ-
mental and Molecular Mutagenesis published by Wiley Periodi-
cals, Inc. on behalf of Environmental Mutagen Society.
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INTRODUCTION
The appropriate interpretation and application of DNA
adduct data to inform risk assessment decisions have been
debated for the past several decades. The intensity of this
debate has increased more recently with the advent of new,
highly speciﬁc, and exquisitely sensitive, analytical
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techniques available to quantify DNA adduct data and the
remarkable insights stemming from new data obtained with
those techniques (Gocke and Müller, 2009, Nakamura
et al., 2014, Swenberg et al., 2011). The growing wealth of
structurally quantitative data on DNA adducts—both those
exogenously induced and those endogenously present from
normal metabolic processes, including background expo-
sures from diet, etc.—provides impetus for an examination
of the role of DNA adducts in the determination of modes
of action (MOA) for adverse outcomes. Indeed, evaluation
of appropriate dose–response models for the key events in
question is also critical. The clear impact of MOA on regu-
latory decisions vis-à-vis linear vs. non-linear dose–
response modelling, in particular, emphasizes the impor-
tance of this issue. Current US EPA regulatory guidance
imposes a linear dose–response model to determine risk
below the identiﬁed point of departure (POD; see text box)
when a mutagenic MOA (sometimes described as a DNA-
reactive MOA) is established for a chemical (U.S. Environ-
mental Protection Agency, 2005). In fact, current practice
often, and quite erroneously, ascribes a mutagenic MOA to
any chemical that causes DNA adducts (often only inferred
from a positive in vitro genetox battery), without the rigor-
ous evaluation of levels of evidence that such a determina-
tion requires. A thorough approach was described by an
International Life Sciences Institute/Health and Environ-
mental Sciences Institute (ILSI/HESI) Committee (Jarabek
et al., 2009), which emphasized the role of DNA adducts
as biomarkers of exposure. This and other approaches have
been applied to some chemicals, offering case studies
(Manjanatha et al., 2017, Pottenger et al., 2014). Indeed,
determination of a mutagenic MOA for cancer cannot
depend solely on a positive in vitro genetox battery but
requires a demonstrated causal link between adduct forma-
tion and induction of in vivo mutations in target tissue in
cancer-related genes (Moore et al., 2018). Thus, an assess-
ment of a chemical that forms DNA adducts (either speciﬁ-
cally quantiﬁed or inferred based solely on positive in vitro
genetox data), can incorrectly conclude it has a mutagenic
MOA, leading to an inappropriate linear extrapolation of
dose–response below the POD, which may result in overes-
timating the actual risk at low dose.
Terminology Related to Dose–Response Modeling
BenchMark Dose (BMD): modelled dose levels corresponding to
speciﬁc response levels, or benchmark responses, near the low
end of the observable range of the data, which serve as possible
points of departure (PODs) for linear or nonlinear extrapolation of
health effects data and/or as bases for comparison of dose–
response results across studies/chemicals/endpoints (U.S. Environ-
mental Protection Agency, 2012). The BMD is estimated by ﬁt-
ting a series of dose–response models to data, and selecting the
best ﬁtting model. An approximate lower conﬁdence bound of the
BMD (BMDL) is suggested to replace the NOAEL as a point of
departure in the health risk assessment of chemical substances.
Break Point Dose (BPD): Similar to Td, the dose–response
model determines the best-ﬁtting two-segment linear function
where the ﬁrst segment from zero dose to the breakpoint is hori-
zontal (i.e., has zero slope) and the second segment has a positive
slope. The inﬂection point where the two lines meet is termed the
BPD (Johnson et al., 2014).
No Observed Genotoxicity Exposure Level (NOGEL): Analo-
gous to a no-adverse-effect-level (NOAEL) value, the NOGEL
value is deﬁned as the highest dose in a genotoxicity assay (in vitro
or in vivo) that does not differ statistically from the control value.
Point of Departure (POD): It is deﬁned as the point on a toxi-
cological dose–response curve established from experimental data
or observational data generally corresponding to an estimated low
observed effect level (LOEL) or no observed effect level (NOEL).
A POD marks the beginning of extrapolation to a toxicological
reference dose (RfD) or reference concentration (RfC). The POD
is an estimated dose near the lower end of the observed range,
without signiﬁcant extrapolation to lower doses (U.S. Environ-
mental Protection Agency, 2005). Extrapolation below the POD
can deﬁne an eventual risk value; safety factors may (or may not)
be applied to a POD.
Threshold: The use of the term “threshold” to describe a dose–
response curve in this paper is considered to be interchangeable with
the term bilinear; it indicates that there are responses in treated sys-
tems (cells, tissues, etc.) that are not quantiﬁably different from con-
trol/background responses and responses that are quantiﬁably
different from control/background responses. Such quantiﬁable dif-
ferences generally are statistically identiﬁed as signiﬁcantly different
from those that are not quantiﬁably different from control/back-
ground values, although not always. Thus, at doses below a “thresh-
old” no (statistically) quantiﬁable increase is measured; at doses
above a “threshold”, there is a (statistically) quantiﬁable difference.
Threshold dose (Td): A Td value is statistically deﬁned by
applying a bilinear dose–response model to a dataset, for which
the lower limit of the conﬁdence interval must be positive (non-
zero) (Lutz and Lutz, 2009). The statistical package compares ﬁt
for the bilinear (Td) model to a linear model and determines
which one is a better statistical ﬁt for the data being modelled,
and when appropriate, the Td value.
Indeed, the available information has grown substantially
in the past 15+ years and has revealed the ubiquitous pres-
ence of endogenous/background DNA adducts, including
pro-mutagenic adducts. In conjunction with new data on
Abbreviations: 4NQO, 4-nitroquinoline-1-oxide; 8-oxo-dG, 8-oxo-
7,8-dihydro-20-deoxyguanosine; AAG, 3-alkyladenine DNA glycosylase;
ACC, American Chemistry Council; alkyl-FAPy, N5-alkyl-2,6-diamino-
4-hydroxy-5-formamidopyrimidine; alkylG, alkyl/hydroxyalkylguanine;
AP site, abasic or an apurinic site; APNG, alkylpurine DNA N-glycosy-
lase; BER, base excision repair; BLEO, bleomycin; BMD, benchmark
dose; BMD/L, benchmark dose lower bound; BPD, break point dose;
BPDL, break point dose lower bound; Ceﬁc, European Chemical Industry
Association; DR, direct reversal; dsDNA, double-stranded DNA; E, ethyl-
ene; ECETOC, European Centre for Ecotoxicology and Toxicology of
Chemicals; EMS, ethyl methane sulfonate; ENU, ethyl nitrosourea; EO,
Ethylene Oxide; FAPy, N5-alkyl-2,6,-diamino-4-hydroxy-5-formamidopyr-
imidine; GTTC, Genetic Toxicology Technical Committee; HE, hydro-
xyethyl; HR, homologous recombination; ILSI/HESI, International Life
Sciences Institute/Health and Environmental Sciences Institute; IVGT, In
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DNA adduct chemistry and fate, including DNA repair,
these provide important new perspectives for understanding
the biological consequences and biological signiﬁcance of
speciﬁc adducts and how to incorporate this information into
risk assessment. This review focuses on research conducted
from 2001–2016 and aims to provide a better understanding
of speciﬁc questions pertaining to N7-guanine adducts
formed from exposure to low molecular weight (LMW)
chemicals, including Ethylene (CAS 74-85-1)/Ethylene
Oxide (CAS 75-21-8) (E/EO) and Propylene (CAS 115-07-1)/
Propylene Oxide (CAS 75-56-9) (P/PO). Much of the experi-
mental work was conducted on recognized, direct-acting muta-
gens: ethyl methane sulfonate (EMS), methyl methane
sulfonate (MMS), ethyl nitrosourea (ENU), and methyl nitro-
sourea (MNU), all also LMW chemicals and typically
employed as positive controls. This article provides some
background on LMW adducts and mutations, followed by an
overview of our now completed research projects, a summary
of what was learned and how it complements other research
conducted with similar focus on the dose–response for muta-
tion induction and the question of thresholds in mutation
response to DNA adducts, and a description of several interna-
tional workshops and committees’ efforts to integrate these
learnings, ending with a look at a path forward. All of this pro-
vides context to the current understanding of the biological
signiﬁcance of N7-alkyl/hydroxyalkylguanine (N7-alkylG)
adducts for risk assessment.
OVERVIEWOFADDUCT FORMATION, STABILITY, AND
FATE: LMWDNA ADDUCTS
Chemistry, Stability, andAdduct Dose-Response of LMW
DNA Adducts
Beginning in the late 1940s/early 1950s, Miller and
Miller pioneered the ﬁeld of chemical carcinogenesis and
were the ﬁrst to demonstrate covalent binding of chemical
carcinogens to macromolecules by reaction with nucleo-
philic sites (electron-rich moieties, S, N, and O) in DNA
and proteins (Miller and Miller, 1947, Wheeler and Skip-
per, 1957). Subsequent in vitro and in vivo studies soon
demonstrated that, under physiological conditions (pH 7.4,
37C), alkylation of DNA primarily occurred at the
N7-position of guanine (Brookes and Lawley, 1961)
(Figure 1). Covalent binding to DNA was shown to occur
mainly via either monomolecular (SN1, e.g., nitrogen mus-
tards) or bimolecular nucleophilic (SN2, e.g., sulfonyl
esters) substitutions (Brookes and Lawley, 1961, O’Con-
nor, 1981, Swenson, 1983, Swenson et al., 1986). Reactive
agents acting via SN1 reactions attack more frequently at
the O6 position of guanine (although still a minor propor-
tion of total adducts), which disrupts hydrogen bonding,
thus producing a higher proportion of the pro-mutagenic
O6-guanine adducts, compared to agents that react solely
via the SN2 mechanism (Beranek, 1990, Singer, 1972,
Singer et al., 1981) (Fig. 1).
Compared to many other DNA adducts, N7-guanine
adducts are chemically unstable, with half-lives in double-
stranded DNA (dsDNA) ranging from as little as 2 h to 150 h
(Margison et al., 1976). For example, the half-life values for
the N7-(2-hydroxypropyl)guanine (N7-HPG) adduct in rat
nasal respiratory epithelium, lung, and liver tissues are 5.5,
5.8, and 6.5 hrs, respectively (Osterman-Golkar et al., 2003).
The particular instability of N7-guanine adducts is due to the
additional positive charge placed on the guanine ring system.
In general, larger alkyl groups promote spontaneous depurina-
tion in dsDNA (King et al., 1979, Margison et al., 1976,
Osborne and Merriﬁeld, 1985). Indeed, unlike most other
DNA adducts, many N7-guanine adducts undergo spontane-
ous depurination. In addition, they can accumulate in DNA
with continuous exposure or treatment, but usually reach a
plateau (steady state) after ~7–10 days of repeated exposure
(Doerge et al., 2005, Lewis and Swenberg, 1980, Walker
et al., 2000, Young et al., 2007). For example, steady state
for the N7-(2-hydroxyethyl)guanine (N7-HEG) adduct is
reached following 7–10 days of repeated exposure to EO
(Walker et al., 2000). At steady state, the number of N7-HEG
adducts formed is equal to the number of adducts lost due to
depurination, repair, or cell death. In contrast, adducts that are
more persistent, such as O4-ethylthymine (O4-ET), continued
to accumulate over an exposure period of 4 weeks
(Boucheron et al., 1987), and O6-methylguanine (O6-MG) in
the brain (where repair is lacking) continued to accumulate
over 6 weeks of dosing (Kleihues and Bucheler, 1977). The
addition of a positive charge on the guanine ring system also
promotes further reactions that have been reviewed in detail
by Gates et al. (2004). The main reactions characteristic for
N7-guanine adducts include: (i) loss of C-8 proton,
(ii) (spontaneous) depurination, (iii) imidazole ring opening to
yield N5-alkyl-2,6,-diamino-4-hydroxy-5-formamidopyrimi-
dine (alkyl-FAPy), (iv) hydrolysis of the N7-alkyl bond, and
(v) rearrangement to C8 adducts.
Relative to guanine itself, N7-methylguanine (N7-MG)
depurinates 106 times more rapidly at pH 7, 37C (Gates
et al., 2004). The frequent spontaneous depurination of
N7-guanine adducts leaves behind an abasic or an apurinic/
molecular weight; MGMT, methylguanine methyl transferase; MMR-
mismatch repair; MMS, methyl methane sulfonate; MN, micronucleus/
micronuclei; MNU, methyl nitrosourea; MOA, mode of action; MPG, N-
methylpurine DNA glycosylase; N1-HEdA, N1-(2-hydroxyethyl)adenine;
N3-HEA, N3-(2-hydroxyethyl)adenine; N7-alkylG, N7-alkyl/hydroxyalkyl-
guanine; N7-HEG, N7-(2-hydroxyethyl)guanine; N7-HPG, N7-(2-hydroxy-
propyl)guanine; N7-MG, N7-methylguanine; N7-OEG, N7-(2-oxoethyl)
guanine; NAS, National Academy of Sciences; NER, nucleotide excision
repair; NOEL, no observed effect level; NOGEL, no observed genotoxic
effect level; O4-ET, O4-ethylthymidine; O6-HEG, O6-hydroxyethylguanine;
O6-1HPdG, O6-(2-hydroxypropyl)-20-deoxyguanosine; O6-2HPdG, O6-
(2-hydroxy-(1-methyl)-ethyl)-20-deoxyguanosine; O6-HPG, O6-hydro-
xypropylguanine; O6-MG, O6-methylguanine; P, propylene; PO, pro-
pylene oxide; POD, point of departure; ROS, reactive oxygen species;
TLS, translesion synthesis
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apyrimidic site (AP site), which is a noninformational
lesion that is recognized as pro-mutagenic (Schaaper and
Loeb, 1981, Neto et al., 1992). In yeast cells, C is preferen-
tially inserted across endogenously generated AP sites, fol-
lowed by the insertion of A, and less frequently of T
(Auerbach et al., 2005). Thus, for an N7-MG-induced AP
site, C insertion is nonmutagenic, while A insertion leads
to G:C to T:A (Gà T) transversions. Although this process
has been proposed as a possible pathway to induce a muta-
tion from an N7-guanine adduct, at least two attempts to
provide evidential support were not successful, with no
clear increases in AP sites identiﬁed in DNA heavily
adducted with N7-guanine adducts (Rios-Blanco et al.,
2000, Rusyn et al., 2005).
Opening of the imidazole ring of N7-alkyl/hydroxyalkyl-
guanine adducts gives rise to related N5-alkyl/hydroxy-
alkyl-2,6-diamino-4-hydroxy-5-formamidopyrimidine adducts
(N5-alkyl/hydroxyalkyl-FAPy) (Pujari and Tretyakova,
2017). This reaction is promoted under alkaline conditions.
Many of these FAPy adducts have been chemically charac-
terized with model compounds (Pujari and Tretyakova,
2017). However, the formation of most N5-substituted FAPy
derivatives remains to be established in cellular DNA. While
data for some large, bulky FAPy adducts, for example, aﬂa-
toxin B1, indicate the FAPy adduct derived from N7-AFB1-G
is more stable than the originating adduct (Brown et al.,
2006, Moore et al., 2018), similar data were not identiﬁed on
the frequency or stability of potential FAPy adducts from the
smaller, LMW adducts addressed in this review.
There is a wealth of data on the formation and dose–
response of LMW N7-alkylG adducts in animal models.
Metabolic activation of E or P to their respective oxides,
EO or PO, via CYP450 activity occurs in all mammalian
tissues investigated. The ubiquitous nature of these oxides,
especially EO, is due to the ubiquitous nature of the parent
oleﬁn, E (and to a lesser degree P), present in natural/
endogenous systems as a product of intermediary metabo-
lism and from background natural and anthropogenic
sources (Swenberg et al., 2008).
The reactive epoxide metabolites can bind to DNA and
form N7-HEG (Fig. 1) or N7-HPG as the major DNA
adduct (>95%). Indeed, there is an endogenous/back-
ground level of these same N7-guanine adducts in all
animal and human tissues investigated (Swenberg et al.,
2011), formed by ubiquitous exposure to endogenous and
other sources of the parent oleﬁn/oxide. These sources
include food, gut bacteria, and normal metabolic pro-
cesses, in addition to combustion (e.g., forest ﬁres, volca-
nos) and anthropogenic sources. The ubiquitous presence
of endogenous/background N7-guanine adducts must be
considered and addressed in any MOA-based risk assess-
ment and evaluation of low exposures to DNA-reactive
chemicals, especially in decisions on selection of appro-
priate dose–response models and PODs (Swenberg
et al., 2008).
The fate of these N7-guanine adducts inﬂuences the
adduct dose–response curves obtained using the very sensi-
tive techniques available. Inhalation studies with E or P in
mice and rats have established adduct dose–response curves
supportive of the saturation of CYP450-mediated metabolic
activation to their respective reactive oxides, which then
form the DNA adducts (Bolt et al., 1984, Bolt and Filser,
1987, Wu et al., 1999, Pottenger et al., 2007, Rusyn et al.,
2005). For example, the metabolism of E to EO in mice sat-
urates at ~1000 ppm E (Bolt et al., 1984, Bolt and Filser,
1987, Wu et al., 1999, Rusyn et al., 2005), producing in
liver ~3.5 N7-HEG/ 107 normal nucleotides (Filser et al.,
1992, Walker et al., 1993). In contrast, direct exposure to
the oxide metabolites produces a linear dose–response for
N7-HEG/N7-HPG (Filser and Bolt, 1983, Filser et al., 1992,
Rios-Blanco et al., 2000, Walker et al., 1993, 2000). The
molecular dose of N7-HEG can be orders of magnitude
greater for exposures to EO than can ever be achieved by E
exposure alone. In subacute or chronic exposures to EO,
N7-HEG adducts increase daily until they reach a steady
state after 7–10 days (Walker et al., 1993, 2000). This non-
linear response over time is attributed to the chemical insta-
bility of N7-HEG and on-going spontaneous depurination.
Similar kinetics have been demonstrated for P vs. PO expo-
sures (Filser et al., 2000, 2001, Rios-Blanco et al., 2000,
2003, Csanády and Filser, 2007, Pottenger et al., 2007).
Mutation Induction by LMWAdducts
Chemical adducts in DNA have been shown to interfere
with DNA replication and transcription. Under most cir-
cumstances, adducts are accurately repaired before DNA
replication occurs. In such cases, there will be no genetic
consequences as the DNA adducts are removed and faith-
fully repaired, and the DNA is restored to its original pri-
mary sequence. In contrast, replication of DNA containing
adducts is likely to generate point mutations in the daughter
Fig. 1. Structures of guanine-cytosine base pairs and ethylene oxide
(EO)-induced adducts: N7-HEG and O6-HEG (SN2 reaction). Disrupted
hydrogen bonding (− − -) shown for O6-HEG, which is unaffected for
N7-HEG. N7-HEG adducts comprise the majority (>95%) of EO-induced
adducts.
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strands at the site of adducts. Pathways that deal with the
presence of lesions in DNA during replication are referred
to as Lesion Tolerance pathways (Fuchs, 2016). These
mechanisms are not genuine repair mechanisms, as they
only allow replication to be completed despite the presence
of lesions, rather than removing them. Figure 2 shows the
main DNA repair pathways focusing on the ones pertinent
to N7-alkylG adducts and O6-alkylG adducts.
A key determinant in potential effects of DNA adducts
is whether or not the particular adduct blocks DNA replica-
tion. Replication-blocking adducts transiently stop the rep-
lication machinery, inducing speciﬁc DNA damage
responses that allow DNA repair to remove residual lesions
genome-wide; some adducts that do not block replication
are thus potentially more mutagenic.
Adducts thatDoNot Block Replication
The efﬁciency with which adducts that do not block rep-
lication are converted into mutations is highly variable
depending on their chemical structure. Some adducts are
converted into point mutations at near stoichiometric efﬁ-
ciency, while others exhibit low intrinsic mutagenic
potency. Illustrative examples include two important alkyl-
ating adducts that are converted into point mutations with
high (O6-alkylG) and low (N7-alkylG) efﬁciency, respec-
tively. Neither N7-alkylG nor O6-alkylG adducts impede
normal replication very much, thus do not block replica-
tion. Mutations triggered by these adducts are, thus, intro-
duced into the genome by the normal replication
machinery. During replication, O6-alkylG adducts pair with
thymine at high frequencies (>80%) instead of with cyto-
sine, due to the disruption of normal hydrogen bond pairing
caused by the adduct (see Fig. 1), thus generating G to A
transitions. In contrast, N7-alkylG adducts are converted
into mutations at very low frequency, that is, below 0.1%.
The intrinsic efﬁciency of conversion of these two alkyl
guanine adducts differs by over three orders of magnitude
(Philippin et al., 2014). It turns out that for adducts that
exhibit high intrinsic efﬁciency of conversion into a muta-
tion during replication, highly efﬁcient, speciﬁc, and some-
times overlapping, repair pathways have been selected by
evolution to repair them before replication in order to mini-
mize mutagenesis during replication. This is the case for
lesions such as O6-MG or 8-oxo-7,8-dihydroguanine
(8-oxoG).
Replication-Blocking Adducts
In contrast, there are many adducts that replication
enzymes cannot bypass. In these cases, after transient paus-
ing of the replicative polymerase, replication resumes
downstream, owing to a re-priming mechanism that leaves
a gap containing the lesion. These gaps are repaired either
accurately by a recombination mechanism that uses the sis-
ter chromatid to recover the missing information, or by
Translesion Synthesis (TLS), an inherently error-prone pro-
cess. Indeed, TLS is mediated by low ﬁdelity polymerases
(TLS polymerases) that tolerate chemical modiﬁcations of
the bases and are able to replicate past the lesion with a
Fig. 2. Schema of DNA damage types and corresponding repair pathways. The present paper focuses on
alkylating damage: repair of alkyl lesions involves Direct Reversal (DR) pathways (via ABH (AlkB
Homolog) or via methylguanine methyltransferase (MGMT)) and Base Excision Repair (BER; AAG
glycosylase); the example of Guanine shows the positions repaired by Direct Reversal in red and the
positions repaired by BER in blue. Pathways not classically involved in alkylating damage repair are shown
to highlight overlap among pathways: for instance, mismatch repair (MMR) is involved in O6-alkylguanine
metabolism leading to toxic repair intermediates. Alkylating adducts bulkier than methyl groups can also be
repaired by nucleotide excision repair (NER).
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high probability of inserting an incorrect base. Among the
many replication-blocking lesions, AP sites, resulting from
the hydrolysis of the N-glycosidic bond between the N9 of
guanine and the C1 of 2-deoxyribose, are perhaps the most
common. The rate of AP site formation is low at normal G
residues (3 × 10−11 sec−1 at 37C) but increases strongly
(over 105-fold) by N7 alkylation (1.4 × 10−6) (Gates et al.,
2004). AP sites are normally repaired by base excision
repair (BER) with AP endonuclease action as a ﬁrst step.
When AP sites are present at the replication fork they
strongly impair DNA synthesis and may elicit a cellular
response, namely the TLS pathways. This entails the tran-
sient recruitment of specialized DNA polymerases that are
able to insert a nucleotide across lesions such as AP sites.
This process is intrinsically mutagenic, potentially leading
to “indirect” mutagenesis by N7-alkylG lesions.
OverviewofDNARepair forN7- andO6-alkylG LMW
Adducts
As shown in Figure 2, there are several DNA repair path-
ways used by cells. The various repair pathways can be clas-
siﬁed into two broad branches determined at the initial
lesion recognition step. On one side, base repair pathways,
either by direct reversal (DR) or by BER, exhibit a lesion
recognition step that involves a protein with high afﬁnity for
one (or a few) lesions (narrow recognition speciﬁcity). In
contrast, nucleotide excision repair (NER) exhibits broad
substrate speciﬁcity that is achieved by several protein com-
plexes that sense perturbations in the structure and/or
dynamics of the DNA double helix induced by lesions with-
out direct readout of the lesion itself. It is viewed more as a
back-up repair for alkylated DNA. N7- and O6-alkylG
adducts are known to be repaired by BER and DR, respec-
tively (Barnes and Lindahl, 2004, Wyatt and Pittman, 2006).
Repair ofN7-alkylGAdducts
Alkylation adducts such as N7-MG (and N3-MA and
N3-MG) are repaired via the BER pathway that is initiated
with recognition and excision of the modiﬁed base by a
DNA glycosylase, followed by repair synthesis for
sequence restoration. The recognition step is carried out by
speciﬁc DNA glycosylases removing the damaged bases by
hydrolyzing the N-glycosidic bond (Kleihues and Margi-
son, 1974). The glycosylase responsible for the repair and
removal of N7-alkylG and N3-alkylA lesions is N-methyl-
purine-DNA glycosylase (MPG), also known as
3-alkyladenine DNA glycosylase (AAG) or alkylpurine
DNA N-glycosylase (APNG) (Gupta et al., 1982, Swenberg
et al., 1984). MPG is a homologue of the E. coli AlkA pro-
tein and is a monofunctional type I glycosylase (Randerath
et al., 1985). Both down-regulation and over-expression of
MPG sensitize cells to methylating agents (Phillips, 2005,
Phillips and Arlt, 2007), suggesting that ﬁne-tuning of the
expression levels of the enzymes involved in BER is essen-
tial for proper function in vivo (Xiao and Samson, 1993,
Coquerelle et al., 1995, Glassner et al., 1998). The later
steps of BER involve repair synthesis, mostly by DNA Pol
β or Pol δ and subsequent ligation.
Repair of O6-alkylGAdducts
O6-MG (and O4-MT) adducts are subject to DR medi-
ated by methyltransferases (also referred to as ATase and
AGT). These proteins repair O6-alkylG adducts in a one-
step, irreversible reaction that transfers the alkyl group
from the O6-oxygen in the DNA to a cysteine residue in
the reactive pocket of methylguanine methyltransferase
(MGMT), thereby restoring the DNA sequence and, in
turn, inactivating the MGMT molecule. As one MGMT
molecule can repair only one alkyl adduct, the cell’s capac-
ity for removing DNA O6-alkylG adducts depends on the
total number of MGMT molecules per cell and its rate of
de novo synthesis (Kaina et al., 2007). Moreover, O6-MG
adducts are also targeted by Mismatch Repair (MMR) pro-
teins leading to cytotoxicity (Klapacz et al., 2009).
Endogenous Exposome
It has become clear in recent years that there exists an
internal milieu called the endogenous exposome that com-
prises a multitude of endogenous reactive chemicals present
ubiquitously in every living system investigated (Nakamura
et al., 2014). These include metabolic products from inter-
mediary metabolism, from normal defense mechanisms,
and from disease processes; examples include ones pro-
duced by gut microﬂora, inﬂammation reaction products,
and oxidative stress products, and ones from reaction to
infections. It is thought that the ubiquitous endogenous
DNA damage resulting from the endogenous reactive
chemicals may drive background/spontaneous mutation
processes. The most abundant endogenous DNA lesion is
the AP site (Nakamura et al., 2000, Swenberg et al., 2011);
these are highly mutagenic if present during DNA replica-
tion (Neto et al., 1992, Schaaper and Loeb, 1981). The next
most abundant endogenous DNA lesions reported are
N7-HEG, N7-(2-oxoethyl)guanine (N7-OEG), and 8-oxoG
(Boysen et al., 2010, Swenberg et al., 2011, Nakamura
et al., 2014). These DNA oxidation products can result
from lipid peroxidation products or reactive oxygen species
(ROS), such as highly reactive hydroxyl radicals that are
formed through a Fenton reaction involving hydrogen per-
oxide (H2O2), itself an abundant endogenous ROS. The
most abundant endogenous DNA lesions after those
mentioned include formaldehyde-related N2-HOMdG and
N6-HOMdA, acetaldehyde-related N2-ethylidenedG and
1,N2-propano-dG, and N7-MG. Incorporation of available
information on the endogenous exposome, the resulting
endogenous DNA lesions, and their expected impact on
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risk, should be integrated with data on chemical-speciﬁc




LMWDNA ADDUCTS INHAZARDANDRISK ASSESSMENT
Consideration of the overall consequence of these issues,
stemming from the demonstrated presence of chemical-
speciﬁc DNA adducts, presented a substantial challenge to
several chemical-speciﬁc panels from the American Chem-
istry Council (ACC) and sector groups from the European
Chemical Industry Association (Ceﬁc). Each of these
groups already had related work on-going, with plans for
more work in this arena. So, the industry groups agreed to
work together in a loose coalition (Joint Industry Group;
JIG1) to provide key data toward elucidation of the biologi-
cal signiﬁcance of DNA adducts, and their appropriate role
in chemical risk assessment. Although not a formal organi-
zation, the JIG coalition shared information among the
members and held several joint meetings to discuss
research results and to co-ordinate plans for further work.
The coalition’s focus was on LMW alkyl/hydroxyalkylG
adducts, based on their chemical products (E, EO, P, and
PO), which were either reactive epoxides (EO, PO) or
could result in the formation of reactive epoxides (E, P),
and had been demonstrated to result predominantly in the
corresponding N7-hydroxyalkylG DNA adducts (N7-HEG,
N7-HPG). These efforts were formally launched in 2001
with a ﬁrst workshop2 described in a published summary
report (Pottenger et al., 2004).
This workshop was designed around three questions that
seemed to highlight the unresolved issues:
 “What does an increase in chemical-speciﬁc DNA
adducts indicate?
 With particular reference to low levels of DNA adducts,
what data demonstrate a consequence or otherwise for
human health?
 What status should DNA adduct measurements have in
overall hazard and risk assessment?”
As described in the publication, the invited academic
experts debated these three questions and, from that debate,
an overall strategy for data collection was developed to
address the gaps identiﬁed. The projects were loosely
deﬁned and were to be conducted roughly in parallel,
although some occurred sequentially; most were conducted
using recognized DNA reactive “positive control” muta-
genic chemicals (ethyl methane sulfonate (EMS), methyl
methane sulfonate (MMS), ethyl nitrosourea (ENU),
methyl nitrosourea (MNU)), and/or the chemicals of spe-
ciﬁc interest (EO and PO). The projects were grouped
around three different approaches to the same question: is
there a threshold for induction of a quantiﬁable level of
mutation/genotoxic effects from these LMW, mostly
N7-guanine DNA adducts.
The ﬁrst approach was the conduct of a series of ‘titra-
tion’ experiments, which compared dose–response curves
for mutation induction (gene mutation and micronucleus
(MN)) by low doses of MMS/MNU and EMS/ENU with
in vitro assays.
The second approach was to structurally quantify
induced DNA adducts and to quantify the resultant induc-
tion of mutation, using high-power analytical techniques
combined with a shuttle vector system for mutation detec-
tion. These experiments were conducted with adducts
resulting from EO exposure.
The third approach utilized site-speciﬁc mutagenesis,
which included synthesis of DNA oligomers with
chemical-speciﬁc DNA adducts incorporated, and then test-
ing of those adducted oligomers in a bacterial mutation
detection system for their mutagenic potency. This permit-
ted comparison between adducts formed by EO and PO
(and their methyl counterparts) and unmodiﬁed guanine
residues to determine their mutagenic potential.
Approaches andResults
The aforementioned three speciﬁc research projects were
supplemented with publication of a review on thresholds in
genotoxicity (Jenkins et al., 2005), and research update
meetings were convened regularly, culminating in research
publications/presentations, and another workshop
(Pottenger et al., 2009b). Additional related work was con-
ducted by the researchers involved which, although not
necessarily funded by JIG member groups, further extended
and complemented the three main projects. Complementary
research and other contributions from a variety of groups
are also described later in this paper.
Dose-ResponseAnalysis ofMutations andChromosome
Damage Induced byDirect-ActingAlkylatingAgents
Doak and colleagues (Doak et al., 2007) described
in vitro gene mutation and chromosome damage dose–
response data for MMS, MNU, EMS, and ENU. These
were evaluated using the AHH-1 human lymphoblastoid
cell line and measuring responses with the hypoxanthine–
guanine phosphoribosyl transferase (HPRT) forward muta-
tion assay and the in vitro cytokinesis-blocked micronu-
cleus (MN) assay, all with a large number of cells and
1The JIG was comprised of the ACC Oleﬁns Panel Ethylene/Propylene
Work Group (E/PWG); the ACC Propylene Oxide/Propylene Glycol
(PO/PG) Panel; the ACC Ethylene Oxide Industry Council (EOIC); the
Ceﬁc Lower Oleﬁns Sector Group (LOSG); the Ceﬁc PO & Derivatives SG
(PO & Der SG); and the Ceﬁc EO & Der SG. Participating groups deter-
mined which projects were of interest to them and co-funded accordingly.
2The 2001 workshop was funded by the Ceﬁc LOSG and the Global PO
Research Group (ACC PO/PG Panel and Ceﬁc PO & Der SG).
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doses (e.g., 8–20 doses tested and up to 5-fold more cells
analyzed than typical for certain doses) tested to maximize
the sensitivity of detection of a response. This dataset pro-
vided a detailed look at the dose–responses for induction of
genotoxic effects by these DNA-reactive chemicals. The
resulting dose–response data demonstrated quantiﬁable no-
observed-genotoxic-effect-levels (NOGELs) for MMS and
EMS with both assays. However, while neither ENU nor
MNU had doses with no increases, statistical NOGELs
were deﬁned in both assays (HPRT and MN) for both
ENU and MNU (for example, see Fig. 3). These dose–
response data were further analyzed using the bilinear/
threshold dose–response modelling approach as described
by Lutz and Lutz (2009), as published by Johnson et al.
(2009). This dose–response modelling approach uses statis-
tics to compare the ﬁt of a dataset to a bilinear/threshold
model with its ﬁt to a linear model, thus allowing for a sta-
tistical determination of a better ﬁt between these two
models and, where appropriate, deﬁning a Threshold dose
(Td) value. The modelled results of the Doak et al. datasets
indicated that the bilinear/threshold model provided a better
ﬁt to the MMS and EMS dose–response data both for gene
mutations and MN induction, while the MNU and ENU
data were mixed. ENU HPRT results were a better ﬁt for
the bilinear dose–response model, while the MN results for
ENU were better described by a linear one; MNU results
could not exclude a linear dose–response model for either
endpoint.
Complementary work conducted by Swenberg and col-
leagues provided some adduct dose–response data to match
the doses evaluated for genotoxic effects by Doak et al.,
(2007). Both endogenous and exogenously-induced
N7-MG and O6-MG were quantiﬁed in AHH-1 cells treated
with stable isotope- and deuterium-labelled MMS
([13C2D3] MMS) or deuterium-labelled MNU ([
2D3]-MNU)
to increase the speciﬁcity and sensitivity for detection of
these adducts and, importantly, to differentiate between
endogenously present adducts (not labelled) and the exoge-
nously induced ones (labelled). The data demonstrated a
linear dose–response for labelled N7-MG (both from MMS
and from MNU), corresponding with exogenously induced
N7-MG adducts, while the endogenous N7-MG did not
increase over the 24-h exposure to either MMS or MNU
(Swenberg et al., 2008, Sharma et al., 2014) (see Figs. 4
and 5). A key ﬁnding from these data comes from compari-
son of the curves for exogenously induced adduct dose–
response to the curves for mutation/genotoxic effect dose–
response, where it becomes apparent that the shape of the
mutation curves and the shape of the molecular dose of
N7-MG are quite different, most notably for MMS. The
Fig. 3. Reprinted (with permission) from Doak et al., 2007: “Figure 1. Inﬂuence of MMS (A), EMS (B), MNU (C), and ENU (D) dose upon
micronucleus frequency in the AHH-1cell line. Points, mean of treatments done in duplicate; bars, SD. *, the ﬁrst statistically signiﬁcant increases in
chromosome damage at 0.85 μg/mL MMS (A), 1.40 μg/mL EMS (B), 0.15 μg/mL MNU (C), and 0.50 μg/mL ENU (D); %Mn/Bn, percentage of
binucleated cells containing one or more micronuclei.”
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labelled N7-MG adducts increase linearly over the dose
range analyzed; however, the genotoxic effects (mutations,
MN) reported by Doak et al. (2007) are nonlinear over that
same dose range, with a low-dose section not showing any
corresponding increase in genotoxic effects (ﬂat slope).
Thus, increasing quantiﬁable levels of (exogenously
induced) DNA adducts (lesions) did not correspond with
an increase in genotoxic response. Together these datasets
demonstrate that there are regions of the low-dose dose–
response where exogenously induced (labelled) N7-MG
adducts are increasing, but with no corresponding quantiﬁ-
able increase in genotoxic response (Figs. 3 and 4). The
N7-MG adduct levels induced at the tested doses were not
pro-mutagenic (did not induce increased mutations), and
therefore do not contribute to increases in genotoxic events
such as mutations or induction of micronuclei. It is likely
that other DNA lesions, ones that are pro-mutagenic lesions
such as the O6-alkylG adducts, are the cause of the geno-
toxic events. Those pro-mutagenic lesions comprise a smal-
ler proportion of total adducts and may not even be present
at such low doses. The adduct proﬁle data published by
Beranek, (1990) would support this hypothesis, as O6-MG
represents only a small proportion of the adduct proﬁles for
all four of these mutagenic chemicals (from not detected to
16.6% in cultured cells and in mammalian liver).
The in vitro experimental work in AHH-1 cells was then
extended at Swansea University, evaluating mutation dose–
response for lower doses, and using DNA repair knock-
down techniques to manipulate the cell’s repair capacity
for more mechanistic analyses. For example, the DNA
repair protein MGMT, which repairs the pro-mutagenic O6-
alkyl-G adduct by removing the alkyl group, was pre-
depleted with O6-benzylguanine pretreatment. The resulting
reduction in DNA repair capacity led to a modiﬁed HPRT
gene mutation dose–response curve following exposure to
MNU. The dose–response curve for genotoxic effects in
cells with pre-depleted repair was non-linear (J-shaped),
substantiating the existence of NOGELs for point mutation
induction by direct-acting alkylating agents. The shifted
dose–response curve led to determination of a lower POD
(NOGEL) for MNU under these conditions compared to
cells with normal MGMT capacity (Thomas et al., 2013).
A different mechanistic approach manipulated the levels of
the DNA repair enzyme MPG, which permanently removes
the alkylated base from the DNA backbone as the ﬁrst step
in BER. This reduction in MPG affected the dose–response
for EMS-induced MN, as the MN POD moved to a lower
Fig. 4. Reprinted (with permission) from Swenberg et al., 2008:
“Figure 8. Comparison of N7-methyl guanine DNA adducts and HPRT
mutations in AHH-1 cells exposed to MMS for 24 h. The endogenous
adducts are N-7Me-G (◇), while the exogenous adducts are [13C2H3]-
7Me-G (♦). The Hprt mutant frequency is shown as (○).”
Fig. 5. Reprinted (with permission) from Sharma et al., 2014: “Figure 1. Endogenous versus exogenous adducts in AHH-1 cells exposed to D3-MNU
(0.0075 μM to 2.5 μM) for 1 h. The endogenous and exogenous O6-me-dG and N7-me-G adducts at each exposure concentration are plotted on a log
versus log scale. Data represent the mean  SD.”
Environmental and Molecular Mutagenesis. DOI 10.1002/em
9EO- and PO-induced DNA adducts and mutations:15 years of data, insights, and collaborative discussions
value after MPG was knocked-down using a speciﬁc RNAi
(Zaïr et al., 2011, Thomas et al., 2013). The cells with
diminished DNA repair capacity demonstrated decreased
POD values compared to similarly treated cells with normal
DNA repair capacity. Therefore, POD metrics (e.g.,
NOGELs) can be deﬁned for the potent alkylnitrosoureas,
MNU and ENU, and when DNA repair is knocked-down
the POD value decreases.
The extensive genotoxicity dose–response data from
Doak et al. (2007) were further analyzed, along with other
examples of similar dose–response datasets, using a wider
toolbox of approaches to deﬁne POD metrics described
later on (Gollapudi et al., 2013, Johnson et al., 2014). Clear
benchmark dose (BMD; BMDL) metrics were derived for
each of these dose–response datasets, and bilinear/threshold
model-derived Break Point Doses (BPD/L) were identiﬁed
for EMS and MMS, based on the Doak et al. (2007) data;
analysis of these data for ENU and MNU did not identify
BPD/L values.
Overall, the in vitro dose–response “titration” data of
dose versus mutations demonstrated that threshold values
or BPDs deﬁned using bilinear/threshold models can be
identiﬁed for genotoxic effects (mutation/MN) caused by
DNA-reactive chemicals. The additional work conducted
by the Swansea and Swenberg labs provided data indicat-
ing that the N7-alkylG adducts were not likely to be the
cause of these genotoxic effects, along with some mecha-
nistic data to explain why these low-dose regions demon-
strate no quantiﬁable increases in genotoxic effects,
informing the MOA for a NOGEL, even with direct-acting
mutagens.
Mutagenic Effects Induced by Exposure to EthyleneOxide
EO is a widely used industrial intermediate in the manu-
facture of chemicals; it is also employed as an agricultural
fumigant and as a sterilizing agent, although these are
minor uses. EO is classiﬁed by the International Agency
for Research on Cancer (IARC) as carcinogenic to humans,
despite conﬂicting epidemiology data regarding the ability
of EO to induce speciﬁc cancers or increase cancer-related
mortality (IARC, 1994, 2008). Moreover, a confounding
factor in evaluating the risks associated with occupational
or environmental exposure to EO is the fact that ethylene is
generated in vivo during normal physiological processes
and can be converted to the epoxide by cytochrome P450
2E1-mediated metabolism (IARC, 1994, 2008). Conse-
quently, humans are constantly exposed to EO, and this is
reﬂected by the fact that N7-HEG adducts are detectable in
isolated lymphocytes from people who were not knowingly
exposed to EO (Zhao and Hemminki, 2002, Yong
et al., 2007).
In order to better understand the signiﬁcance of DNA
damage induced by EO, and any resulting mutations, it is
important to ascertain which speciﬁc EO adducts have
mutagenic potential (are pro-mutagenic), and to perform
studies at doses and damage levels that are relevant to
human exposures. When EO reacts with DNA, the most
abundant product formed, N7-HEG, is not thought to be
directly pro-mutagenic; however, it readily depurinates
leaving AP sites that have miscoding potential if not
repaired before replication occurs (Takeshita et al., 1987).
Minor amounts of N3-(2-hydroxyethyl)adenine (N3-HEA)
and O6-HEG have also been identiﬁed from this interaction
in vitro, while 2-hydroxyethylation can also occur at the
N1 and N6 positions of adenine (Tompkins et al., 2008).
The supF forward mutation assay, a shuttle vector assay,
has been used to investigate the biological relevance of low
levels of EO-induced DNA adducts in human cells. The
aim was to determine whether there is a level of tolerable
DNA damage, below which notable increases in mutations
are not induced; in addition, extensive analytical work
would begin to address the speciﬁc role of different HE-
DNA adducts (Tompkins et al., 2009). This assay involves
in chemico treatment of a shuttle vector plasmid carrying
the supF gene, which is then transfected and replicated in
human cells in culture followed by recovery and screening
for the presence of mutations in E. coli. Any plasmids with
a mutated supF gene can then be characterized by sequenc-
ing, thereby providing a quantitative assessment of muta-
genic potency for the compound of interest and a mutation
spectrum. A major advantage of this approach is the ability
to proﬁle the type and level of damage present on the plas-
mid prior to transfection into human cells; this quantiﬁca-
tion was conducted for EO using a validated liquid
chromatography–tandem mass spectrometry (LC–MS/MS)
assay capable of detecting ﬁve different HE-adducts (see
Fig. 6) (Tompkins et al., 2008). In an initial study, expo-
sure to “low” concentrations of EO (0.01 to 2 mM) gener-
ated levels of N7-HEG in the plasmid that far exceeded
those typically detected in human DNA, but no other HE-
lesions were detectable. This level of damage failed to pro-
duce a notable increase in mutation frequency in supF
above background rates when replicated in cells. The muta-
tion spectrum was not different from the spontaneous distri-
bution, indicating that the N7-HEG adduct did not result in
quantiﬁable increases in mutation with the supF assay,
despite the heavy N7-HEG adduct load. Thus, EO is not
strongly mutagenic in this system and N7-HEG itself has
low mutagenic potential (Tompkins et al., 2009).
It took much higher EO concentrations (10 mM EO for
24 h) to induce any quantiﬁable increase in mutation fre-
quency. At this very high dose, the minor lesions
N1-HEdA, O6-HEdG, and N3-HEdU were detected in
treated plasmid along with high levels of N7-HEdG. These
ﬁndings imply that either a certain level of total adducts or
speciﬁc pro-mutagenic adducts must be present before
mutations become evident above background. Based on
comparison of these results with published data for other
genotoxic compounds analyzed in the supF forward
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mutation system, it was concluded that EO is a relatively
weak mutagen in human cells.
Given that EO is produced in humans from the metabo-
lism of ethylene generated during physiological processes,
it is essential to determine the relative contribution of the
ever present endogenous versus exogenously derived DNA
damage and its consequence, to allow for more accurate
human risk assessments. This became possible through the
use of a dual-isotope approach that enabled delineation of
the in vivo dose–response relationships in rats over a con-
centration range relevant to human EO exposures, includ-
ing doses associated with occupational sources (Marsden
et al., 2009). Although this project was funded separately
by the ACC Long Range Initiative (LRI) and was not part
of the JIG research efforts, it is described here since the
ﬁndings are integral to understanding the role of EO-
induced damage and any associated risks. By combining
LC–MS/MS analysis and the extremely sensitive technique
of HPLC-accelerator mass spectrometry (AMS), both the
endogenous and exogenous ([14C]-labelled) N7-HEG
adducts were quantiﬁed in tissues of [14C]-EO-treated
(i.p. injection) rats (Marsden et al., 2007, 2009). Although
levels of [14C]-N7-HEG induced in DNA extracted from
treated rat tissues increased in a quasi-linear manner, the
level of adducts arising via this route was negligible com-
pared to the much higher natural background abundance of
endogenous N7-HEG present (see Fig. 7). The implications
of this result are that exogenous N7-HEG formation may
not pose any additional risk over and above that presented
by the ubiquitous background damage, at least up to the
tested (high, i.p.) doses. It is worth noting that, at the two
highest doses studied (0.05 and 0.1 mg EO/kg bw,
i.p. injection), administration of [14C]-EO substantially
increased the endogenous N7-HEG levels in the liver and
spleen of treated rats, suggesting EO can induce physiolog-
ical pathways responsible for ethylene generation in vivo




























Fig. 7. Reprinted (with permission) from Marsden et al., 2009. “Figure 2. Contribution of endogenously
and exogenously derived N7-HEG to the total adduct level in tissues of [14C]EO-treated rats. Endogenous
adducts were determined by LC–MS/MS. Exogenous 14C-labelled adducts were quantiﬁed by AMS and are
shown as black bars on top of bars representing endogenous adduct levels. Columns, mean of three animals
per group; bars, SD. *, P < 0.05, the level of endogenous N7-HEG in tissues of [14C]EO-treated rats is
signiﬁcantly higher than the corresponding background level in control animals; **, P < 0.05, the total level
of adducts (endogenous plus exogenous) is signiﬁcantly higher than the level of endogenous adducts alone
in a particular tissue.”
























Fig. 6. Reprinted (with permission) from Tompkins et al., 2008.
“Figure 4. HPLC chromatogram demonstrating the separation of
hydroxyethyl (HE) nucleoside adducts from unmodiﬁed nucleosides, using
the conditions employed for the isolation of nucleoside-HE adducts.
Synthetic adduct standards have been used to produce this trace for
illustrative purposes; in a typical digested DNA sample HE adducts would
not usually be present at detectable levels and fractions would be collected
on the basis of retention time.”
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Overall, the experimental data demonstrate that EO is
only weakly mutagenic in the supF system, as quantiﬁable
increases were only observed following exposure to high
concentrations, and that EO-induced (exogenous) N7-HEG
adduct levels are overwhelmed by endogenous N7-HEG
adduct levels across a range of EO doses (i.p. injection).
Mutagenic Response to Site-specificallyModifiedDNA
Probes
The goal of this JIG project was to test the N7-alkyl/
hydroxyalkylguanine adducts of interest speciﬁcally for
their capability to induce a mutagenic response, using site-
speciﬁc mutagenesis techniques. This direct test of their
mutagenic potential seemed a logical next step, although it
posed many challenges. The ﬁrst challenge was the insta-
bility of N7-alkyl/hydroxyalkylG adducts as discussed pre-
viously, and whether synthesized adducted oligomers were
stable enough to test. Thus, the decision was to test the O6-
alkylG adducts ﬁrst, as a positive control and a good ﬁrst
proof-of-principle. O6-alkylG adducts are considered pro-
mutagenic and so should induce mutations in the bacterial
detection system.
Synthesis andPuri¢cation of Single-adductedOligonucleotides
Two main approaches exist for the preparation of DNA
probes with O6- and N7-HEG/HPG adducts, taking into
account the well-documented instability of N7-alkylG
adducts.
Site-speciﬁc synthesis of O6-HEG containing
oligonucleotides. The chemical synthesis of oligonucleo-
tides that contain any of the three O6-alkylG adducts
including O6-HEG, and the two HPG isomers: O6-
(2-hydroxypropyl)-20-deoxyguanosine and O6-(2-hydroxy-
(1-methyl)-ethyl)-20-deoxyguanosine, was achieved by
adapting the well documented solid-phase phosphoramidite
method (Mazon et al., 2009). Thus, a convenient, O6-pro-
tected, building block was synthesized and site-speciﬁcally
inserted into deﬁned sequence oligonucleotides. Activation
of the modiﬁed guanine moiety allowed a speciﬁc reaction
with hydroxyethanol, 1-hydroxypropanol, or 2-hydroxy-
propanol, to generate O6-HEG and the PO-derived isomers:
O6-1HPG, and O6-2HPG, respectively.
Preparation of N7-(2-hydroxyalkyl)-guanine containing
DNA fragments. However, the above synthetic method
was not appropriate for the preparation of the N7-alkyG
containing oligonucleotides due to the instability of both
the N-glycosidic bond and the potential for opening of the
imidazole ring of the 7-substituted guanine 20-deoxyribonu-
cleosides. Therefore, a less ﬂexible alternative strategy was
applied. A 13-mer DNA fragment with only one guanine
residue was treated with an excess of EO or PO and the
main alkylation products were puriﬁed by HPLC. Thus
oligonucleotides containing N7-HEG and N7-HPG were
prepared (Philippin et al., 2014). These lesions were stable
in isolated DNA when left in aqueous solutions at RT up
to several days (Gasparutto et al., 2005). The lack of muta-
genicity discussed below (Philippin et al., 2014) indicated
a lack of detectable formation of the highly mutagenic AP
sites or the pro-mutagenic formamidopyrimidine ring-
opened derivatives from the N7-G adducts (within the time
frame of the experiment). Any more direct proof of the
apparent lack of any formation of N5-hydroxyalkyl-FAPy
adducts in both isolated and cellular DNA awaits further
targeted measurement experiments, for example with an
LC–MS/MS assay that allows the unambiguous detection
of non-substituted FapyG, an oxidatively generated guanine
lesion (Cadet et al., 2010). This could be eventually accom-
panied by the mutagenic assessment of N5-hydroxyalkyl-
FAPy lesions using a similar strategy that was applied for
related N7-substituted guanine adducts.
Repair ofN7- andO6-alkyl/hydroxyalkylguanineAdducts:
Distinct andNovel Repair Strategies toRemoveDNA Adducts
As discussed earlier, N7-alkylG and O6-alkylG adducts
use different repair strategies, with N7-alkylG adducts rely-
ing mainly on BER, often following depurination (Gates
et al., 2004, Boysen et al., 2009), while the O6-alkylG is
repaired via DR with the removal of the alkyl group by
MGMT. Interestingly, during the course of this project, a
novel pathway that bridges BER and NER was identiﬁed
(Mazon et al., 2009, 2010). As the size of the alkyl group
increases, the repair of O6-alkylG adducts appears to
default to NER (Kaina et al., 1983, Margison et al., 2007,
Tubbs et al., 2009, Aramini et al., 2010). Although not
described here in any detail as tangential to the focus of
this review, it seems this observation represents a novel
paradigm showing that proteins with high binding afﬁnity
to speciﬁc lesions may be instrumental to channel proces-
sing of speciﬁc lesions from BER to NER, thus showing
the key role played by the size of the O6-substituent in the
selection of the repair mode.
Tolerance ofN7- andO6-alkylGAdductsDuringReplication in
WholeCells/Assessment of their IntrinsicMutagenic Potential
In order to assess how these adducts are processed dur-
ing replication, a double-stranded plasmid vector contain-
ing a single N7- or O6-alkylG adduct was constructed
(Mazon et al., 2010, Philippin et al., 2014). The main focus
of the work was to determine the mutagenic potential of
adducts formed by EO and PO, compared to their methyl
and unmodiﬁed counterparts. N7-alkylG adducts, such as
N7-HEG and N7-HPG, have never been speciﬁcally tested
previously, likely due to lack of stability from rapid depuri-
nation. To assess the potential effect of these adducts on
DNA polymerase bypass activity we measured the effect of
these adducts on replication in bacteria. In order to achieve
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maximal sensitivity single-stranded plasmid probes carry-
ing a single lesion were used. Under these very stringent
conditions, colonies can only arise after successful replica-
tion across the single adduct. In addition, single-stranded
plasmids are particularly stringent probes for replication, as
adducts cannot be removed by repair. The N7-MG adduct
did not impair replication, while the N7-HEG and N7-HPG
adducts reduced the transformation efﬁciency substantially,
to ≈70% and 40% relative to the unmodiﬁed construct,
respectively. Interestingly, no signiﬁcant loss in transforma-
tion efﬁciency was observed with any of the O6-alkylG
adduct carrying probes relative to the unmodiﬁed construct,
indicating that these pro-mutagenic adducts exhibit no
(or only weak) replication-blocking potential. Taken
together, when compared to major replication-blocking
lesions such as UV-induced pyrimidine dimer lesions that
cannot be bypassed by the normal replication, but require
the TLS machinery instead, neither the N7- nor the O6-
alkylG adducts severely affect normal replication.
Lack ofN7-alkylGAdduct-inducedMutagenesis
To investigate the intrinsic mutagenic potential of N7-
and O6-alkylG adducts, single-stranded DNA probes con-
taining single adducts were evaluated. As stated previously,
the O6-alkylG adducts, considered as pro-mutagenic, were
tested ﬁrst as a proof-of-principal approach (Mazon et al.,
2009, 2010). As O6-alkylG may potentially be repaired by
ATase-mediated reversal, even when present in single-
stranded DNA, the mutant fraction was assessed in an
ATase-deﬁcient E. coli strain (ada ogt mutS). Under these
stringent conditions, as adducts can neither be repaired by
alkyl transfer nor by NER, plasmid progeny production
necessarily relies on replication through the single adduct.
All O6-alkylG adducts (including both O6-HEG and O6-
HPG) were highly mutagenic (mutant fraction >80%),
implying that correct insertion of a C across the O6-alkylG
adducts is a minor event (<20%). As expected from reports
on O6-MG mutagenesis, sequencing of the mutants
obtained with the different adducts under investigation
demonstrated that they resulted from mis-insertion of T
across from O6-alkylG, leading to G ! A transition muta-
tions (Bartsch, 1996, van Zeeland, 1996, De Bont and van
Larebeke, 2004, Rundle, 2006). In the repair proﬁcient
wild-type (WT) strain, O6-MG-induced mutagenesis is lost
due to efﬁcient ATase-mediated repair. In sharp contrast,
the hydroxypropyl adducts (O6-1HPG and O6-2HPG)
remained as mutagenic in the WT strain as in the repair
defective ada ogt strain, indicating no or only limited repair
via DR. With the O6-HEG adduct, a partial reduction of
the mutant fraction was observed in the WT strain com-
pared to the ada ogt strain, illustrating moderate repair of
this adduct by the WT ATase proteins.
The results for the N7-alkyl/hydroxyalkylG adducts were
in sharp contrast to the above. Prior to evaluating the
N7-alkylG adducts, the presence of depurinated molecules
was minimized. Following introduction of these probes into
E. coli cells, the effect of the N7-alkylG adducts on the
ﬁdelity of replication was determined. Within the detection
limit of the assay, replication across the N7-alkylG adducts
in vivo (in bacterial cells) was essentially error-free, as no
mutant colony was observed among ≈1000 individual
sequenced colonies (i.e., mutation frequency < 0.1%)
(Philippin et al., 2014). Given these unprecedented results,
the experiment was repeated with the exact same
outcome—no mutations detected from any of the
N7-alkylG adducts tested. Thus, the completely reproduc-
ible results demonstrated a lack of mutagenicity for these
N7-alkyl/hydroxyalkylG adducts, including N7-HEG and
N7-HPG. This is the ﬁrst such demonstration of a lack of
mutagenicity for LMW N7-alkyl/hydroxyalkylG adducts.
JIGResearchConclusions
In summary, the research program sponsored by JIG pro-
vided substantial data to address questions on dose–
response relationships for adduct formation, mutation
induction, and the relationship between some speciﬁc
adducts, including chemical-speciﬁc adducts that are
derived from both endogenous and exogenous sources, and
mutation induction. In all cases, the data demonstrate that
these relationships can be non-linear, with the LMW
N7-alkylG adducts (N7-HEG, N7-HPG) proving not to be
mutagenic when speciﬁcally tested in site-speciﬁc mutagen-
esis assays.
As a follow-up to the aforementioned workshop that
launched the JIG effort, a second workshop was held in
September 2008 as a satellite of the EEMGS (European
Environmental Mutagen and Genomics Society) annual
meeting, which included reviewing the recent data against
the original three questions. It was jointly sponsored by
ECETOC (European Center for EcoToxicology), ILSI/
HESI, and JIG. An overview of that follow-up workshop,
which included participation from the scientists who devel-
oped the data described above, along with other academic,
industry, and regulatory scientists, and some regulators
from Europe and the US, was published to share the ﬁnd-
ings (Pottenger et al., 2009b). The program comprised pre-
sentations of technical data and discussions around
regulatory applications and implications, along with break-
out sessions on speciﬁc questions. Several consensus state-
ments were developed at the end of the workshop, includ-
ing ones addressing the following:
“DNA adducts should be considered as biomarkers of
exposure, which may play a key role in establishing a mode
of action (MOA) for cancer. Adducts themselves should
not be considered as equivalent to mutations or later stage
events in carcinogenesis. Although it was not possible at
this time to agree on a general level of adducts below
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which there is no adverse biological effect, there are exam-
ples of genotoxic mutagens/carcinogens for which bilinear/
“thresholds” have been demonstrated3. Evidence regarding
“thresholds” for mutations should be considered on a case-
by-case basis, in light of available MOA and mechanistic
data, to build a knowledge base.”
Workshop participants agreed that it would be useful to
develop guidance on a recommended format for data pre-
sentation (especially agreement on units and appropriate
statistical analyses) — something that has been addressed
since by the ILSI/HESI group as discussed later. Finally, a
recommendation was made that early cases needed data to
support a mechanistic explanation for any hypothesis of a
“threshold” for mutations; this was considered essential to





As the data and work products described above were
being developed and became available, it was important to
integrate the new approaches and new information into the
larger picture, with the many, separate, contemporaneous
efforts contributing to the debate. There were substantial
efforts to address these questions by many researchers col-
lecting similar data, with in vitro and in vivo models. Some
work was directly complementary, other work was seren-
dipitously independently corroborative. In addition, the
new data were integrated with work products from interna-
tional committees and with ideas brought forward from
other workshops addressing interpretation and methods, all
aimed at incorporation and acceptance of the learnings into
MOA analysis and risk assessment—the ultimate goal.
Implications from JIG-sponsoredWork
The ground-breaking analytical work built on Lindahl’s
much earlier efforts (Lindahl, 1993), with both stable iso-
topes and radioisotopes identifying and quantifying the
many endogenously present DNA adducts. These included
pro-mutagenic adducts and adducts that are chemically
identical to speciﬁc chemical-induced ones, all found in tis-
sues from untreated control animals under steady-state con-
ditions as described earlier (Swenberg et al., 2008, 2011,
Nakamura et al., 2014). The growing database on endoge-
nously present adducts has opened new avenues of per-
spective, leading to a paradigm shift that is still playing out
in recognizing the impact of this information on back-
ground issues and on risk assessment. Some of the chal-
lenges are depicted in Figure 8. The idea that there is a
background of a variety of DNA adducts (shown as green
hashed region in Fig. 8A) ubiquitously present, offered a
possible explanation for the well-recognized background of
spontaneous mutations (shown as grey hashed background
in Fig. 8B), quantiﬁed in every properly controlled mutage-
nicity experiment for decades. The spontaneous/back-
ground mutations are thought to be due to incomplete or
inadequate DNA repair of the background/endogenous
DNA adducts. Those background/endogenous adducts
derive from many sources, including endogenous reactive
species formed during cellular processes, metabolism of
DNA, etc. The ubiquitous endogenous background for
adducts (Fig. 8A) and for mutations (Fig. 8B) render depic-
tion of dose–response below the background a challenge—
one that is overcome for the adduct dose–response by
employing the speciﬁc and sensitive techniques with stable/
radio isotope-labelled chemicals described above. Thus, it
is possible to track chemical-speciﬁc adduct levels below
the endogenous background, where one predicts a linear
decrease to the starting point; this can be shifted due to
e.g., required metabolism to reactive forms (green line in
Fig. 8A). It is important to recognize a critical difference in
information available from adducts compared to
mutations—that chemical-speciﬁc DNA adducts can be
linked to a speciﬁc chemical exposure, because they retain
chemical-speciﬁc information related to their source. It may
require sophisticated techniques to distinguish endogenous
from exogenous chemical-speciﬁc adducts, but it is feasible
to do so.
On the other hand, mutations do not retain chemical-
speciﬁc information, thus it is impossible to demonstrate
unequivocally the source of a speciﬁc mutation. There is
no speciﬁc analogous analytical marker retained with a
mutation that links them to a speciﬁc exogenous chemical
exposure. However, in some cases, sequencing of muta-
tions can tie them to a speciﬁc class of mutation that may
be linked with a speciﬁc exposure. Aﬂatoxin B1 and G:C
àT:A transversions in codon 249 of p53 provide such an
example (Moore et al., 2018). For the most part, it is not
possible to determine the source (e.g., endogenous vs exog-
enous, and if exogenous, what exposure) of a mutation in
the region below the endogenous background level,
depicted in Figure 8B with question marks. Thus, a DNA
adduct represents a biomarker of exposure, one that can be
linked to a speciﬁc chemical exposure, while a mutation, as
a heritable change in the primary DNA sequence, repre-
sents a biomarker of genotoxic effect.
Of course, although this discussion is focused on adducts
and mutations, expression of a mutation requires more than
just an adduct. Cell proliferation to ﬁx the mutation is just
one critical step in an MOA for mutation induction
(Pottenger and Gollapudi, 2010). Indeed, tissue-speciﬁc
3Some examples of in vivo datasets that demonstrate thresholds for geno-
toxic mutagens/carcinogens include the work on EMS published by
(Gocke and Müller, 2009), and in vivo data on MMS published by
(Ji et al., 2016), which demonstrates a threshold for induction of
micronucleus.
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and cell-speciﬁc proliferation rates have been shown to
drive differences in tissue mutation rates (Long et al.,
2018). Once the mutant frequency rises above the endoge-
nous background level (depicted with the grey hashed
lines), it generally increases until either the rate plateaus
due to metabolic saturation of formation of the reactive
metabolites responsible for the mutations, or it increases
theoretically until cell death from toxic damage. However,
understanding the dose–response for these adducts, whether
endogenously present or exogenously induced, and how
they relate to the possible outcome of induced mutation
(above the background or spontaneous level), is a key
aspect of this work. Although it is impossible to determine
the dose–response for induced mutations within the region
of background/spontaneous mutations, the important infor-
mation for risk assessment is understanding at what expo-
sures this genotoxic response surpasses the background/
spontaneous level.
Complementary Efforts
Substantial complementary research efforts have gener-
ated many published datasets, including some extensive
ones, to measure mutation dose–response curves and, in
several cases, incorporating exposure biomarkers of inter-
nal dose and dose–response. Key results from several
research groups, including both in vitro and in vivo work,
are brieﬂy described below.
The dose–responses for genotoxic effects from a series
of DNA-reactive chemicals were evaluated in vitro for
induction of micronucleus with ﬂow cytometry measure-
ments, and large numbers of doses and cells were evaluated
to strengthen the statistical evaluations; these included vin-
blastine sulfate (VB), EMS, MMS, ENU, MNU, and bleo-
mycin (BLEO) (Bryce et al., 2010). The authors concluded
that all the test chemicals except BLEO had dose–
responses that demonstrated a better statistical ﬁt with a
nonlinear dose–response model than a linear one. Similar
in vitro dose–response data for induction of gene mutation
(TK) in mouse lymphoma cells by DNA-reactive chemicals
MMS and MNU demonstrated a better statistical ﬁt for a
nonlinear model for MMS results, while the MNU results
did not show a better ﬁt for the nonlinear model (Pottenger
et al., 2009a). These results are similar to the results Doak
and colleagues (Doak et al., 2007) published for
MMS/EMS and MNU/ENU as described above; the early
data for alkylnitrosoureas appeared to ﬁt a linear model bet-
ter than a non-linear one. However, further work with
MNU showed that it was more a question of how low a
dose was tested, as Thomas and coworkers (Thomas et al.,
2013) later demonstrated that MNU exhibited a non-linear
dose–response, based on additional data collected at lower
doses.
Several recent in vivo datasets on nitrosamines and other
direct-acting mutagens focused on dose–response and con-
tributed additional weight-of-evidence for non-linear dose–
response with DNA-reactive chemicals. Perhaps the stron-
gest dataset came from the Hoffmann-LaRoche researchers,
as it included internal dosimetry (hemoglobin adducts) in
addition to gene mutation (Muta™Mouse) and MN induc-
tion as measures of in vivo genotoxic events, over a range
of doses of EMS and ENU (see Fig. 9) (Gocke and Müller,
2009). The hydroxyethylvaline adducts clearly increased
steadily with increasing EMS dose, as would the predicted
N7-EG adducts based on Murthy and colleagues (Murthy
et al., 1984), representing an increasing internal dose. How-
ever, the markers of genotoxic effect did not increase above
control levels until the EMS dose was above 20–50 and
80 mg/kg bw, for lacZ mutations and MN, respectively
(Gocke and Müller, 2009). Several lower EMS doses did
not result in any quantiﬁable increase in either gene muta-
tion (lacZ) or MN levels. The data for ENU did not show
Fig. 8. Schematic representation of theoretical dose–response curves for Biomarkers of (A) Exposure (DNA adducts) and (B) (Genotoxic) Effect
(Mutations). Hashed regions represent background levels. Exogenous Compounds Requiring Metabolic Activation. Exogenous Reactive Direct-
Acting Compounds. Endogenous Reactive Direct-Acting Compounds.
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the same threshold/BPD dose–response result, although the
authors discuss how lower doses might have demonstrated
a dose–response similar to EMS. Indeed later work did
demonstrate such a threshold (and BPD) in rats for the
in vivo induction of pig-A mutations in erythrocytes follow-
ing 28-d repeated dosing with either EMS (21.9 mg/kg bw)
or ENU (0.88 mg/kg bw), based on a better statistical ﬁt
for a threshold dose–response model (Dobo et al., 2011).
Additional work with MNU and pig-A demonstrated no
increases of CD59− reticulocytes or erythrocytes for
repeated doses (28 d) of MNU (0.1 to 1.25 mg/kg),
whereas the MN frequency was induced at doses above
0.3 mg/kg bw, again demonstrating a low-dose region with
no increases in genotoxic effects for in vivo tests (Lynch
et al., 2011). Adding to the weight of evidence for non-lin-
ear/threshold dose–responses, a similar dataset was
obtained with 4-nitroquinoline-1-oxide (4NQO), a direct-
acting genotoxicant, and pig-A, where repeated exposures
(28 d) to 4NQO at the lowest dose of 1.25 mg/kg bw also
did not result in statistically signiﬁcant increases in CD59−
reticulocytes or erythrocytes, nor in increased peripheral
blood micronuclei (Stankowski et al., 2011). In fact, this
kind of work was expanded beyond DNA-reactive chemi-
cals with the work of Olipitz and colleagues (Olipitz et al.,
2012), who evaluated exposure of mice to low-dose radia-
tion and measured subsequent mutation induction, along
with gene expression changes in several marker genes for
DNA repair and cell cycle effects. Their data demonstrated
that repeated whole body exposure to low doses of ionizing
radiation (400-fold background levels, 0.0002 cGy/min for
5 weeks) did not result in any signiﬁcant increases in
markers for genotoxic effects. They found no increases for
the indirect radiation-induced DNA adducts (8-oxo-dG,
εdA, εdC), double strand breaks (DSBs), MN, or homolo-
gous recombination (HR), as assessed with the ﬂuorescent
yellow direct repeat reporter assay. They also did not ﬁnd
any increases in DNA damage response by gene expression
of several markers for DNA repair. Historically, approaches
to estimate cancer risk from chemicals have been based on
methods derived from radiation data by the NAS (National
Academy of Sciences, 1977), as described by Calabrese
(Calabrese, 2013). Thus, identiﬁcation of doses that do not
result in signiﬁcant increases in genotoxic effects for both
DNA-reactive chemicals and for radiation corroborates that
there are low-dose regions with no quantiﬁable increases in
genotoxic effect responses, or “thresholds”, supporting
determinations of PODs or BPDs.
The question of low-dose linearity for mutation induc-
tion dose–response has also been investigated for the high
production volume LMW chemical oleﬁn/oleﬁn oxide
pairs, ethylene/ethylene oxide (E/EO) and propylene/pro-
pylene oxide (P/PO). These data add to the weight-of-
evidence for “thresholds”/BPDs in the dose–response of
adducts vs. mutations, especially the LMW N7-alkylG
adducts. Work conducted on E/EO and on P/PO provide
insights on these questions with in vivo data, demonstrating
that heavy burdens of N7-alkylG adducts from repeated
ethylene exposures (N7-HEG) (Rusyn et al., 2005) or from
repeated propylene (Pottenger et al., 2007) or PO exposures
(N7-HPG) (Rios-Blanco et al., 2000) did not result in quan-
tiﬁable increases in AP sites, a mechanism proposed to lead
to mutation induction from depurination and inadequate
repair of N7-alkylG adducts (Neto et al., 1992). In addition,
in vivo mutation assays of E- and P-exposed rats (and mice
for E) did not result in any increases in HPRT mutations
(or MN), despite heavy N7-alkylG adduct burdens (Walker
et al., 2000, Pottenger et al., 2007). Data on in vivo muta-
tion from EO itself show that exposures at or below
10–50 ppm EO do not result in any quantiﬁable increases
in the genotoxic effect markers evaluated in somatic cells
(HPRT mutations, reciprocal translocations, micronucleus),
but increases were quantiﬁable at higher doses (Sisk et al.,
1997, Walker et al., 1997, van Sittert et al., 2000, Recio
et al., 2004, Donner et al., 2010). More recently an exten-
sive assessment of in vivo mutation induction in mouse
lung by repeated exposures to EO utilized the Allele-
speciﬁc Competitive Blocker Polymerase Chain Reaction
approach to quantify dose–response for mutations induced
in a cancer-relevant gene, Kras, along with measuring
adducts and transgenic mutations in mouse lung (Haber
et al., 2013, Parsons et al., 2013, Manjanatha et al., 2017).
The investigators reported that, despite dose-dependent
increases in N7-HEG adducts, no statistically signiﬁcant
(p < 0.05) increases were found for Kras (or cII) mutations
in mouse lung exposed to 10 ppm EO for 4 weeks of
repeated exposure. There were statistically identiﬁed
increases observed at 50 ppm in some tissues, although it
is not clear whether these resulted from EO-speciﬁc DNA
adducts or from indirect mechanisms such as oxidative
stress. Together these in vivo mutation studies consistently
show non-linear dose–response curves for induction of
Fig.9. Reprinted with permission from Gocke and Müller, 2009, “Fig. 3.
Frequencies of micronuclei as function of ethylvaline levels. MN-PCE
values are plotted for each mouse against the ethylvaline levels.
Independent linear regression lines were ﬁtted for animals receiving
≤80 mg/(kg day) and for animals receiving ≥80 mg/(kg day).”
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genotoxic/mutagenic effects, where low exposures result in
quantiﬁably increased DNA adduct levels but no concomi-
tant quantiﬁable increases in genotoxic/mutagenic effects.
Integrationwith Contributions from International
Workshops&Committees
Parallel to and following collection of the experimental
data, it is necessary to interpret and integrate the new infor-
mation. Analysis of approaches for applying these new data
to risk assessment were topics of several international com-
mittees and workshops. The tripartite organization, ILSI/
HESI, held a workshop in 2004 (Sander et al., 2005) as a
kick-off to an ILSI/HESI Project Committee on the Biolog-
ical Signiﬁcance of DNA Adducts. A framework for analy-
sis and interpretation of DNA adduct data was developed
(Himmelstein et al., 2009, Jarabek et al., 2009) and applied
to three case studies (Tamoxifen, aﬂatoxin B1, and vinyl
chloride) to demonstrate how DNA adduct data could be
applied to MOA determination and risk assessment
(Pottenger et al., 2014). Some key conclusions from this
10-year effort included the following:
 “The ubiquitous existence of endogenous DNA adducts
(often chemically identical with induced ones) must be
considered in the overall assessment.
 Not all DNA adducts are considered pro-mutagenic or
lead to a heritable effect; an adduct is not equivalent to a
mutation.
 Adduct data alone cannot be used to predict a quantita-
tive cancer risk.
 Dosimetry considerations are critical; thus adduct data
must be integrated with other relevant data, such as
PK/TK, environmental and background exposures,
adduct fate, system status (e.g., healthy or not), etc.
 While in vitro data can provide useful information, they
cannot inform quantitative risk assessment if collected at
concentrations that are unachievable for in vivo
situations.
 To establish a DNA-reactive MOA, it is necessary to
demonstrate pro-mutagenic DNA adducts in the target
tissues for carcinogenicity; some mutations in critical
genes (e.g., p53; ras) in tumors should be attributable to
chemical-speciﬁc DNA adducts detected in the target
tissue.”
The work in the ILSI/HESI project committee dovetailed
with the early work in a related ILSI/HESI Committee, the
In Vitro Genetic Toxicity (IVGT), which later broadened
its purview and became the Genetic Toxicology Technical
Committee (GTTC), still working today. One key topic that
this expert group addressed was quantitative dose–response
modelling of genetic toxicology data, in an effort to bring
genetic toxicology into the same realm as the rest of toxi-
cology disciplines, developing quantitative methods to
apply to dose–response of genotoxic effects to inform risk
assessment. The ILSI/HESI GTTC carried out extensive
dose–response analyses on all adequate in vitro and in vivo
gene mutation and micronucleus dose–response datasets for
MMS, EMS, MNU, and ENU that were published pre-
2012. In a report by Gollapudi and colleagues (Gollapudi
et al., 2013), data available for EMS and MMS were
assessed, and clear POD metrics were deﬁned for each
dose–response, with NOGEL, BPD/L, and BMD/L metrics
being deﬁned for each dose–response dataset. Available,
adequate MNU and ENU dose–response data were then
assessed in a second effort, using a wider range of statisti-
cal approaches (Johnson et al., 2014), in addition to those
employed previously. This analysis showed that the bilin-
ear modelling approach (Lutz and Lutz, 2009) had some
major drawbacks (e.g., required extensive data), such that
BPD/L metrics could only be deﬁned in ~5% of the cases.
However, when the BMD-1SD and BMD-10% approaches
were used, BMD/L metrics were deﬁned in all cases. These
ﬁndings indicate that the ‘threshold’ dose–response model-
ling provided within the bilinear approach is less suitable
for robustly deﬁning a POD with a standard dataset. This
along with other information, resulted in the ILSI/HESI
GTTC and International Workshops on Genotoxicity Test-
ing (IWGT) 2013 expert groups (MacGregor et al., 2015a,
2015b) recommending the BMD/L approach as best for
deﬁning POD metrics for genotoxic effects. One other
major recommendation was that, although statistically
deﬁned ‘thresholds’ can be determined using large datasets
with bilinear dose–response modelling, the BMD/L model
allows for smaller numbers of animals to be used, and more
precise POD metrics to be deﬁned; however, this is done
with acceptance that low levels of even DNA-reactive gen-
otoxicants pose negligible concern to the human popula-
tion. Additional aspects of mutation dose–response were
explored in a HESI-sponsored workshop in 2014 (White
and Johnson, 2016), including further analysis of metrics
and comparing results across in vivo transgenic rodent
models and tissues, with recommendations on how to use
BMD/Ls to address potency from in vivo mutation data
(Wills et al., 2017).
Other contributions to the data and discussions around
these issues included several papers on related topics, such as
a proposed description of a mutagenic MOA by Pottenger
and Gollapudi that deﬁned potential key events leading to
genetic effects, and discussed determination of the MOA for
no effects, at the NOGEL—why we do not see mutations or
other genotoxic effects at doses where we have adducts
(Pottenger and Gollapudi, 2010). One by Klapacz and col-
leagues (Klapacz et al., 2016) also provided insights on these
issues stemming from a 2014 SOT symposium that raised
similar questions about the mechanisms underpinning non-
linear/bilinear genotoxic dose-responses. With a focus on net-
working of DNA repair pathways, they integrated informa-
tion to illustrate the biological pathways and networks
involved in repair and homeostatic processes for various
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types of DNA damage. Indeed, evaluation of these key cellu-
lar responses should be an integral part of research designed
to provide MOAs for NOGELs and PODs for genotoxic
effects for compounds of interest, including known
mutagens.
CONCLUDINGREMARKS
Therefore, after 15+ years of work by a multitude of
researchers on many fronts, and putting all this information
together, it is time to ask: did we answer our three original
questions:
 What does an increase in chemical-speciﬁc DNA
adducts indicate?
 With particular reference to low levels of DNA adducts,
what data demonstrate a consequence or otherwise for
human health?
 What status should DNA adduct measurements have in
overall hazard and risk assessment?
Based on all the above, the answer is ‘yes, in large part’.
Given the extensive amount of data now available on DNA
adducts (both exogenous and endogenous), and on dose–
response for the induction of genotoxic effects (in vitro and
in vivo), coupled with the advancements in interpretation and
methods for quantitative dose–response modelling and assess-
ment allowing for the determination of PODs useful for risk
assessment, and the progress in the mechanistic understanding
of and determination of MOA, this large body of complemen-
tary work has provided the ﬁeld with a different perspective
on what is known and what else might be useful.
Overall, the collective, collaborative research efforts of
the past 15+ years have raised the understanding of the bio-
logical mechanisms employed in DNA damage and repair
and its consequences, resulting from new techniques and
measurement capabilities. A wealth of data is available to
explain why an adduct does not equal a mutation and to
conﬁrm the ubiquity of endogenously formed DNA
adducts. These data help elucidate the MOAs of agents at
their NOGEL values and in the regions of dose–response
curves with no increase in genotoxic effects despite
increased DNA adducts. They provide quantitative methods
to derive BMD/Ls and other PODs for genotoxic effects,
and examples of how such data can and cannot be used to
inform risk assessment of chemicals that are DNA-reactive.
Indeed, future considerations should focus on the analysis
using the BMD/L approach, as this is now recommended
over the bilinear/threshold and NOGEL approaches
(Gollapudi et al., 2013, Johnson et al., 2014). As data and
additional examples continue to be developed and pub-
lished, we reach a point where we have to ask how much
information is enough to determine negligible concern
(e.g., setting exposure limits), whether empirical PODs,
such as a NOGEL, or a modelled POD, such as a BMD;
perhaps the data now available on LMW N7-alkylguanine
adducts should lead the way. The 2008 ECETOC work-
shop (Pottenger et al., 2009b) was not able to reach consen-
sus on the speciﬁc question of what level of DNA adducts
would be considered as exposures associated with negligi-
ble risk. Certainly, with the increased current mechanistic
understanding that was identiﬁed as necessary, coupled
with the consensus that DNA adducts are considered bio-
markers of exposure and not biomarkers of genotoxic
effect, the conditions are ripe. Thus, with the additional
site-speciﬁc mutagenesis data demonstrating that N7-HEG
and N7-HPG are not mutagenic, and all the additional
in vitro and in vivo mutation datasets demonstrating clear
NOGELs for direct-acting mutagens (MNU, ENU, MMS,
EMS, 4NQO, etc.), with more in vivo transgenic mutation
data coming, we are ready to reach a consensus on a level
of DNA adducts—perhaps it would only be for LMW
N7-alkylG adducts—that would be considered of negligible
concern. This might even be applied in a similar way to the
application of concentration cut-off values with the Glob-
ally Harmonized System of classiﬁcation approach, or pos-
sibly in potency determinations as discussed by Hennes
et al. (2014). Questions such as how broadly these exam-
ples and this growing database can be extrapolated, and
how many data are enough, are critical to address as a sci-
entiﬁc body. With a goal of informing risk assessment, reg-
ulatory acceptance of these insights and application of
them in regulatory situations remain a key challenge, one
that can only be addressed by the regulatory community,
itself, in applying the many learnings from the recent sci-
ence as described above. The necessary tools, such as
BMDs and PODs, and the data, are available and sufﬁ-
ciently mature for use by the regulatory community. We
will all learn from that application.
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